ACET · Insider Trading
Adicet Bio, Inc. Common Stock
Every open-market purchase and sale reported by ACET officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-08-07 | Lloyd Klickstein | Chief Medical Officer | A | +18,300 deriv. | — |
| 2026-08-07 | Lloyd Klickstein | Chief Medical Officer | A | +18,300 deriv. | — |
| 2026-06-23 | Lloyd Klickstein | Director | A | +4,200 deriv. | — |
| 2026-06-23 | Blake Aftab | Chief Scientific Officer | A | +55,000 deriv. | — |
| 2026-06-23 | Andrew Sinclair | Director | A | +4,200 deriv. | — |
| 2026-06-23 | Katie Peng | Director | A | +4,200 deriv. | — |
| 2026-06-23 | Jeffrey Chodakewitz | Director | A | +4,200 deriv. | — |
| 2026-06-23 | Michael Grissinger | Director | A | +4,200 deriv. | — |
| 2026-06-23 | Chen Schor | President & CEO | A | +55,000 deriv. | — |
| 2026-06-23 | Steve Dubin | Director | A | +4,200 deriv. | — |
| 2026-04-29 | Rajeev M. Shah | 10%+ Owner | J | −1,000,000 | — |
| 2026-04-13 | RA CAPITAL MANAGEMENT, L.P. | 10%+ Owner | Buy | +894,384 | +$6.42M |
| 2026-04-09 | OrbiMed Israel GP Ltd. | 10%+ Owner | Sell | −837,264 | −$5.40M |
| 2026-03-27 | Brian Nicholas Harvey | Chief Financial Officer | A | +43,361 deriv. | — |
| 2026-03-27 | Chen Schor | President & CEO | A | +468,555 deriv. | — |
| 2026-03-27 | Julia D. Maltzman | Chief Medical Officer | A | +72,555 deriv. | — |
| 2026-03-27 | Don Healey | Chief Technology Officer | A | +43,361 deriv. | — |
| 2026-03-27 | Blake Aftab | Chief Scientific Officer | A | +72,555 deriv. | — |
| 2026-01-27 | Brian Nicholas Harvey | Chief Financial Officer | F | −546 | −$4.61K |
| 2026-01-27 | Don Healey | Chief Technology Officer | F | −535 | −$4.52K |
| 2026-01-27 | Chen Schor | President & CEO | F | −1,755 | −$14.81K |
| 2026-01-27 | Blake Aftab | Chief Scientific Officer | F | −535 | −$4.52K |
| 2025-10-10 | OrbiMed Israel BioFund GP Limited Partnership | 10%+ Owner | Buy | +40,000,000 | +$40.00M |
| 2025-06-13 | Jeffrey Chodakewitz | Director | A | +5,900 | — |
| 2025-06-13 | Andrew Sinclair | Director | A | +5,900 | — |
| 2025-06-13 | Katie Peng | Director | A | +5,900 | — |
| 2025-06-13 | Steve Dubin | Director | A | +5,900 | — |
| 2025-06-13 | Lloyd Klickstein | Director | A | +5,900 | — |
| 2025-04-21 | Michael Grissinger | Director | A | +70,200 deriv. | — |
| 2025-02-04 | Don Healey | Chief Technology Officer | A | +275,000 deriv. | — |
| 2025-02-04 | Julia D. Maltzman | Chief Medical Officer | A | +750,000 deriv. | — |
| 2025-02-04 | Chen Schor | President & CEO | A | +763,829 deriv. | — |
| 2025-02-04 | Blake Aftab | Chief Scientific Officer | A | +275,000 deriv. | — |
| 2025-02-04 | Brian Nicholas Harvey | Chief Financial Officer | A | +324,040 deriv. | — |
| 2025-01-28 | Brian Nicholas Harvey | Chief Financial Officer | F | −8,752 | −$8.07K |
| 2025-01-28 | Blake Aftab | Chief Scientific Officer | F | −6,270 | −$5.78K |
| 2025-01-28 | Chen Schor | President & CEO | F | −28,101 | −$25.90K |
| 2025-01-28 | Don Healey | Chief Technology Officer | F | −8,560 | −$7.89K |
| 2024-06-07 | Katie Peng | Director | A | +5,900 | — |
| 2024-06-07 | Don Healey | Chief Technology Officer | A | +271,595 deriv. | — |
| 2024-06-07 | Jeffrey Chodakewitz | Director | A | +5,900 | — |
| 2024-06-07 | Chen Schor | President & CEO | A | +1,770,427 deriv. | — |
| 2024-06-07 | Blake Aftab | Chief Scientific Officer | A | +336,911 deriv. | — |
| 2024-06-07 | Francesco Galimi | SVP & Chief Medical Officer | A | +375,077 deriv. | — |
| 2024-06-07 | Aya Jakobovits | Director | A | +5,900 | — |
| 2024-06-07 | Steve Dubin | Director | A | +5,900 | — |
| 2024-06-07 | Brian Nicholas Harvey | Chief Financial Officer | A | +374,829 deriv. | — |
| 2024-06-07 | Carl L Gordon | Director | A | +5,900 | — |
| 2024-06-07 | Michael Kauffman | Director | MIXED | — | −$8.44K |
| 2024-06-07 | Andrew Sinclair | Director | A | +5,900 | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. | 10%+ Owner | 1,033,605 | $4.07M |
| Rajeev M. Shah | 10%+ Owner | 932,624 | $3.67M |
| Andrew Sinclair | Director | 133,318 | $525.27K |
| OrbiMed Israel GP Ltd. | Director | 78,499 | $309.29K |
| OrbiMed Israel BioFund GP Limited Partnership | Director | 40,416 | $159.24K |
| Chen Schor | President & CEO | 9,536 | $37.57K |
| Lloyd Klickstein | Chief Medical Officer | 6,785 | $26.73K |
| Brian Nicholas Harvey | Chief Financial Officer | 5,145 | $20.27K |
| Don Healey | Chief Technology Officer | 3,452 | $13.60K |
| Blake Aftab | Chief Scientific Officer | 2,981 | $11.75K |
| Steve Dubin | Director | 1,419 | $5.59K |
| Jeffrey Chodakewitz | Director | 1,106 | $4.36K |
| Katie Peng | Director | 738 | $2.91K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the ACET quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.